Biotech Companies Wary Of CMS Plans For Cost-Effectiveness Research
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS Administrator nominee McClellan is expected to "pick up and continue" where former Administrator Scully left off in controlling drug prices, Ligand marketing exec Erwin says at BIO conference.